肺表面活性物质联合经鼻间歇正压通气治疗新生儿呼吸窘迫综合征

Pulmonary surfactant combined with nasal intermittent positive pressure ventilation treatment for neonatal respiratory distress syndrome

目的观察肺表面活性物质联合经鼻间歇正压通气治疗新生儿呼吸窘迫综合征(NRDS)的临床疗效。方法 66例NRDS患儿根据随机数字表法分为试验组36例和对照组30例,分别给予珂立苏、固尔舒配合经鼻间歇正压通气治疗。结果两组患儿治疗后肺功能指标a/APO2、PaO2/FiO2均明显提高,与治疗前比较差异有统计学意义(P<0.01),氧合功能好转;试验组和对照组治疗有效率分别为94.4%、96.7%,两组比较差异无统计学意义(P>0.05)。结论两种药物联合经鼻间歇正压通气治疗NRDS均有显著疗效,但进口PS制剂固尔舒价格相对国产PS制剂珂立苏昂贵,在临床可根据患者的情况选择使用。

Objective To observe the clinical efficacy of pulmonary surfactant combined with nasal intermittent positive pressure ventilation treatment for neonatal respiratory distress syndrome（NRDS）. Methods 66 NRDS ca ses were divided into treatment group（ n =36 ） and control group（ n = 30 ）, cases according to the table of random num ber method, kelisu and curosurf were given respectively as same as the nasal intermittent positive pressure ventilation therapy. Results The lung function index a/APO2, PaOJFiO2 of the two groups were obviously improved （ P 〈 0. 01 ）,and the oxygenation function was improved; The effective rates of treatment group and control group were 94.4 % and 96.7 % respectively, there was no significant difference between the two groups （ P 〉 0.05 ）. Conclusion The two drugs combined with nasal intermittent positive pressure ventilation treatment for NRDS is effective, but the price of curosurf is more expensive than kelisu, and patients can choice one of them according to their situation.